Clinical Study Results
In our first clinical study, conducted in Sweden on 30 women diagnosed with bacterial vaginosis, the product provided an efficient clearance of bacterial vaginosis.
Microbial results indicate that the pathogens were restricted while the number of protective lactobacteria increased, hence re-establishing a healthy vaginal bacterial flora.
During the study, no adverse events were assessed to be treatment related, and all were resolved by the end of study. After this first clinical study, the treatment appears to be on par with results achieved with local antibiotic treatment, but with superior symptom control.
According to this first study it appears that the product could prove to be a treatment option to local antibiotics. Thus, contributing to the fight against arising global microbial resistance to common antibiotics.
The product has been tested for antimicrobial effect in vitro demonstrating powerful antimicrobial activity on bacterial vaginosis and gonorrhea bacteria.
In an in vitro study the antimicrobial effect on two pathogens, Gardnerella vaginalis and Neisseria gonorrhea has been investigated. Both species have the ability to produce catalases, a hydrogen peroxide degrading enzyme.
The results indicate that a dilution of 1:100 of Pharmiva’s first product leads to total inhibition of both Neisseria gonorrhea and Gardnerella vaginalis.
Innovations in Women’s Health
We are in our mission committed to reducing the threat of bacterial tolerance development to antibiotics by offering alternative and effective treatment methods.
Sankt Lars Väg 45B
222 70 Lund
+46 (0)46 286 51 00